<DOC>
	<DOCNO>NCT01448200</DOCNO>
	<brief_summary>PPI-668 antiviral agent ( hepatitis C NS5A inhibitor ) develop potential treatment hepatitis C virus infection . This study do assess safety tolerance PPI-668 give healthy volunteer 5 day ( Part I study ) hepatitis C patient 3 day ( Part II ) . In addition , study assess much PPI-668 absorb bloodstream . In Part II , effect PPI-668 amount hepatitis C virus patient ' bloodstream ( serum HCV RNA level ) also assess .</brief_summary>
	<brief_title>A Phase 1 Study PPI-668 Healthy Volunteers Patients With Hepatitis C Virus ( HCV ) Genotype 1</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>In order participate study , volunteer Part I patient Part II must meet follow key entry criterion , well entry criterion specify full protocol : Key Inclusion Criteria 1 . Male female , 18 65 year age . Female patient must surgically sterile two year postmenopausal . 2 . Body Mass Index ( BMI ) 18 35 kg/m2 3 . In good health , judgment Principal Investigator 4 . Able willing comply protocol requirement sign inform consent . Key 1 . Seropositive HIV antibody , HBV surface antigen ( HBsAg ) Screen . Volunteer subject Part I must also negative HCV antibody . 2 . Any medical condition may interfere absorption , distribution elimination study drug ( PPI668 ) , clinical laboratory assessment study . 3 . Poorly control unstable hypertension ; sustain systolic BP &gt; 150 diastolic BP &gt; 95 Screen . 4 . History Diabetes Mellitus treat insulin hypoglycemic agent 5 . History alcohol abuse illicit drug use , investigator 's judgment , could interfere patient 's compliance , protocol requirement safety efficacy assessment study 6 . History malignancy unless malignancy complete remission without additional medical surgical intervention precede three year 7 . No clinically significant laboratory abnormality Screen healthy volunteer Part I . For Screen laboratory parameter HCV patient Part II , refer 'Additional Criteria HCV Patients ' . Additional Key Entry Criteria HCV patient ( Part II ) : 1 . Clinical diagnosis chronic hepatitis C , document : 1 . Clinical finding compatible chronic hepatitis C , absence know liver disease 2 . Seropositive HCV antibody HCV RNA least previously , Screen 3 . Serum HCV RNA &gt; 5 log10 IU/mL Screen , PCR assay central study laboratory 4 . HCV genotype1 ( 1a 1b , nonsubtypable genotype1 ) , HCV genotype2a genotype3a 2 . ALT must &lt; 5 x ULN screen 3 . No previous treatment interferon , pegIFN , ribavirin genotype1 patient 4 . No history sign symptom decompensated liver disease 5 . Any following laboratory value Screening exclusionary study participation : Hgb &lt; 11 g/dL woman 12 g/dL men . White blood cell count &lt; 4,000/mm3 . Absolute neutrophil count ( ANC ) &lt; 1800 per mm3 . Platelet count &lt; 100,000 per mm3 . Serum creatinine &gt; ULN central study laboratory . Serum albumin &lt; 3.4 g/dL . Total bilirubin &gt; 2.0 mg/dL Clinically significant abnormality electrocardiogram ( ECGs ) Screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>hepatitis C</keyword>
	<keyword>NS5A inhibitor</keyword>
	<keyword>Phase 1</keyword>
	<keyword>genotype-1</keyword>
	<keyword>genotype-2</keyword>
	<keyword>genotype-3</keyword>
</DOC>